Imunon, Inc.
LSE: 0HUZ.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stacy R. Lindborg
- Employees
- 25
- Headquarters
- Lawrenceville, United States
- IPO year
- 2018
- Market cap
- $2.2M
- Website
- https://www.imunon.com
Loading 0HUZ…
Loading profile data…Frequently asked questions about 0HUZ
What does Imunon, Inc. (0HUZ.L) do?
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulati...
Where does 0HUZ.L trade?
Imunon, Inc. (0HUZ.L) trades on the London Stock Exchange.
What sector is 0HUZ.L in?
Imunon, Inc. (0HUZ.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Imunon, Inc.?
Stacy R. Lindborg is the chief executive officer of Imunon, Inc. (0HUZ.L).
Where is Imunon, Inc. headquartered?
Imunon, Inc. is headquartered in United States.
Does 0HUZ.L pay a dividend?
Imunon, Inc. (0HUZ.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HUZ.L go public?
Imunon, Inc. (0HUZ.L) completed its initial public offering in 2018.